Christopher Halloran

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma

John P. Neoptolemos, Malcolm J. Moore, Trevor F. Cox et al. · JAMA · 2012 · 592 citations

Medicine, Oncology, Surgery +17

Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial

Markus K. Diener, Christoph M. Seiler, Inga Rossion et al. · The Lancet · 2011 · 553 citations

Medicine, Perioperative Medicine, Surgery +14

Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial

William Greenhalf, Paula Ghaneh, John P. Neoptolemos et al. · JNCI Journal of the National Cancer Institute · 2013 · 333 citations

Medicine, Cancer Biology, Oncology +16

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 325 citations · Full text

Medicine, Oncology, Surgery +16